![]() |
| Photo Credit: Fernando Zhiminaicela |
Oxford University researchers have unveiled a new blood test, powered by machine learning, which shows real promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect.
Named TriOx, this innovative test analyses multiple features of DNA in the blood to identify subtle signs of cancer, which could offer a fast, sensitive and minimally invasive alternative to current detection methods.
The study, published in Nature Communications, showed that TriOx accurately detected cancer (including in its early stages) across six cancer types and reliably distinguished those people who had cancer from those that did not.
Cancers are more likely to be cured if they’re caught early, and early treatment is also much cheaper for healthcare systems. While the test is still in the development phase, it demonstrates the promise of blood-based early cancer detection, a technology that could revolutionize screening and diagnostic practices.
A team of researchers at the University of Oxford have developed a new liquid biopsy test capable of detecting six cancers at an early stage. The cancer types evaluated in this study were colorectal, esophageal, pancreatic, renal, ovarian and breast.


_MoreDetail-v3_x1_1190x750.jpg)
.jpg)



.jpg)
.jpg)
